Fig. 4 | Communications Biology

Fig. 4

From: 90Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin’s Lymphoma

Fig. 4

90Y-NM600 TRT achieves complete tumor responses with a favorable safety profile. a Growth of EL4 tumor after treatment with increasing IA of 90Y-NM600. An IA-dependent tumor growth inhibition was noted with complete tumor regression in the groups administered 2 × 4.63 MBq and 9.25 MBq of activity. b Overall survival. A significant improvement in survival was achieved in all treatment arms except the 18.5 MBq cohort; however, mice administered 90Y-NM600 2 × 4.63 MBq or 9.25 MBq exhibited complete responses (CR) in 60% (3/5) and 80% (8/10) of the subjects, respectively. c Body weight of treated mice. A noticeable decrease in body weight was observed in the 9.25 MBq and 18.5 MBq IA groups. d Normal tissue histology at day 150 after treatment. H&E staining of tissues slides of the kidneys, liver, bone marrow, and spleen shows normal morphology in CR mice compared to vehicle-treated controls. Scale bar represents 100 μm. e Comprehensive blood chemistry panel. No statistical difference was found in any of the blood markers compared to vehicle-treated controls. All numerical data are presented as mean ± SD

Back to article page